Skip to main content
. 2014 Nov 25;211(10):1585–1596. doi: 10.1093/infdis/jiu660

Figure 2.

Figure 2.

Impact of human immunodeficiency virus (HIV) treatment on cytokine and chemokine levels in subjects positive for both HIV and GB virus C (GBV-C; cases) and subjects positive for HIV and negative for GBV-C (controls). A, For the 25 cases and 18 controls who initiated highly active antiretroviral therapy (HAART) during the Viral Activation Transfusion Study, visit spacing was reorganized around the first day of HAART use. Red dots are for the first visit with a GBV-C RN–positive sample. B, Median percentage changes in cytokine/chemokine levels after initiation of HAART are represented for cases and controls.*P < .05, **P < .1, for comparison of cases to controls. Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-α2, interferon α2; IFN-λ1, interferon λ1; IL-6, interleukin 6; IL-7, interleukin 7; IL-8, interleukin 8; IL-10, interleukin 10; IL-19, interleukin 19; IL-20, interleukin 20; I-TAC, interferon-inducible T-cell α chemoattractant; LIF, leukemia inhibitory factor; TARC, thymus- and activation-regulation chemokine; TNF-α, tumor necrosis factor α.